Personalizing treatment targets for IGF-1 in Pediatric Growth Hormone Deficient Patients

Summary

Understanding how individual patients respond to treatment is the heart of personalized medicine. This study aims to understand how Insulin-like Growth Factor 1 (IGF-1), a marker of Growth Hormone function in the body, may be used to help determine how patients with Growth Hormone Deficiency are responding to treatment early on.

Eligibility

Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 1 to 18

Inclusion criteria:

This study is open to any patients from ages 1 to 18 who are diagnosed with Growth Hormone Deficiency or short stature.

Exclusion criteria:

1) Patients with kidney failure
2) Liver disease
3) Growth hormone resistance
4) Genetic syndromes that are known to be associated with short stature (e.g. Prader Willi or Turner Syndrome)

Participate

Fill out the following form if you want to participate in this research

Method of contact

Collection of personal information
Your personal information is collected under the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If you have any questions about the collection or use of this information, please visit our Access to Information page.

Additional information

Contact information

Dennis Orton, PhD FCACB Clinical Assistant Professor | University of Calgary

Principal investigator:

Dennis Orton

Clinical trial:

No

REB-ID:

REB21-0109